- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MERUS LABS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MPH HEALTH CARE | 21,400 | +3,88 % | Original-Research: MPH Health Care AG (von First Berlin Equity Research GmbH): Kaufen | Original-Research: MPH Health Care AG - from First Berlin Equity Research GmbH
21.11.2025 / 12:01 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 12,455 | -2,66 % | EyePoint Pharmaceuticals, Inc.: EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration | - No changes in protocol recommended for LUGANO and LUCIA clinical trials - - Masked safety data continues to show no safety signals, consistent with previous clinical trials for DURAVYU - - On track... ► Artikel lesen | |
| AMARIN | 13,600 | -0,73 % | Amarin Corporation plc: Amarin Reports Second Quarter 2025 Financial Results | -- European Partnership with Recordati Established to Maximize VAZKEPA® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 1,376 | -1,15 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification | - Final Analysis Anticipated by Year-End Upon Occurrence of 80 Events - NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS'' or the... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 20,630 | +2,28 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update | Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 508,40 | -1,17 % | Madrigal Pharmaceuticals: Aktie erreicht Rekordhoch von 578,8 US-Dollar | ||
| ANI PHARMACEUTICALS | 71,00 | 0,00 % | ANIP vs. AMRX: Which Niche Drugmaker Is the Better Pick? | ||
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information | Northvale, New Jersey--(Newsfile Corp. - November 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| DOGECOIN CASH | - | - | Dogecoin Cash, Inc.: Dogecoin Cash Inc. (OTCQB:DOGP) Announces Special Distribution of DogeCoin Cash (MEMECOIN:DOG) to Shareholders | MESQUITE, NV, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Mesquite, NV - Dogecoin Cash Inc. (OTCQB:DOGP) today announced that its Board of Directors has approved a special distribution of DogeCoin Cash (MEMECOIN:DOG)... ► Artikel lesen | |
| BLUM HOLDINGS | - | - | BLUM HOLDINGS, INC. - 8-K, Current Report | ||
| BMP PHARMA TRADING | 4,800 | 0,00 % | PTA-News: B.M.P. Pharma Trading AG: Konzern weiterhin auf Erfolgskurs - Die Gesellschaft steigert das operative Halbjahresergebnis im Geschäftsjahr 2025 | DJ PTA-News: B.M.P. Pharma Trading AG: Konzern weiterhin auf Erfolgskurs - Die Gesellschaft steigert das operative Halbjahresergebnis im Geschäftsjahr 2025
Unternehmensmitteilung für den Kapitalmarkt... ► Artikel lesen | |
| THERIVA BIOLOGICS | 0,269 | +4,27 % | Theriva Biologics, Inc.: Theriva Biologics Reports Third Quarter 2025 Operational Highlights and Financial Results | - Expanded data for VCN-01 (zabilugene almadenorepvec) in metastatic pancreatic ductal adenocarcinoma (PDAC) from the VIRAGE Phase 2b trial presented at the European Society for Medical Oncology (ESMO)... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 10,550 | +5,92 % | Kazia Therapeutics Limited: Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory ... | SYDNEY, Nov. 18, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with... ► Artikel lesen | |
| ALLERGY THERAPEUTICS | 0,105 | +1,94 % | Allergy Therapeutics to explore dual listing in Hong Kong | ||
| ACURA PHARMACEUTICALS | - | - | ACURA PHARMACEUTICALS, INC - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB |
Das Unternehmen MERUS LABS INTERNATIONAL INC kann der Branche Pharma zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MERUS LABS INTERNATIONAL INC finden Sie auf Wallstreet Online.